<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791838</url>
  </required_header>
  <id_info>
    <org_study_id>BOT-1</org_study_id>
    <nct_id>NCT05791838</nct_id>
  </id_info>
  <brief_title>Experience in Borderline Ovarian Tumors</brief_title>
  <official_title>Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent&#xD;
      an independent disease entity among epithelial ovarian cancers. The present study aimed to&#xD;
      report the 8-year experience of a single center on the management and outcomes of consecutive&#xD;
      BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical&#xD;
      treatment were included. Demographic, clinical, and pathological data were reviewed&#xD;
      retrospectively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2023</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Oncological outcome</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Patients who underwent surgery for BOT</description>
  </primary_outcome>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Borderline Ovarian Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients surgically treated for borderline ovarian tumors (BOT)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years,&#xD;
&#xD;
          -  Patients affected by borderline ovarian tumors (BOT) of any histological type and any&#xD;
             FIGO stage,&#xD;
&#xD;
          -  Women undergoing surgical treatment with both laparoscopic and laparotomic approaches.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Women affected by ovarian cancers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basilio Pecorino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Scollo, M.D. Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Catania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Simone Lagan√†, M.D. Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Etrusco, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Palermo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Etrusco, M.D.</last_name>
    <phone>+393881715032</phone>
    <email>etruscoandrea@gmail.com</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>February 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>March 17, 2023</last_update_submitted>
  <last_update_submitted_qc>March 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Andrea Etrusco</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Conservative surgery</keyword>
  <keyword>Micropapillary patterns</keyword>
  <keyword>Surgical staging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

